DRG Epidemiology's coverage of non-small cell lung cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of non-small cell lung cancer for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are also forecast across the world.

DRG Epidemiology's non-small cell lung cancer forecast will answer the following questions:

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the countries considered in this report. These patient flow diagrams are provided at the regional level, but may be requested for any specific country or forecast year.

In addition to the total number of cases for each forecast year, DRG Epidemiology also provides at least ten years of forecast data for the following non-small cell lung cancer subpopulations:

Note: coverage may vary by country.

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with non-small cell lung cancer per year?
  • In developing countries, what impact will economic growth and development have on the number of people diagnosed with non-small cell lung cancer per year?
  • How will improvements in survival change the number of first-line drug-treatment opportunities for non-small cell lung cancer?
  • How will decreasing recurrence risk change the number of first-line drug-treatment opportunities for non-small cell lung cancer?
  • Of all people diagnosed with non-small cell lung cancer, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of non-small cell lung cancer over the forecast period?
    • Diagnosed incident cases - adenocarcinoma by ALK translocation status
    • Diagnosed incident cases - adenocarcinoma by EGFR translocation status
    • Diagnosed incident cases - adenocarcinoma by KRAS mutation status
    • Diagnosed incident cases - adenocarcinoma by stage and resection status
    • Diagnosed incident cases - NSCLC by ALK translocation status
    • Diagnosed incident cases - NSCLC by EGFR mutation status
    • Diagnosed incident cases - NSCLC by KRAS mutation status
    • Diagnosed incident cases - squamous by stage and resection status
    • Diagnosed incident cases - unverified by stage at diagnosis
    • … and many more (details available on request).

Table of contents

  • Epidemiology Dashboard
    • Introduction
      • NSCLC Epidemiology Dashboard

Author(s): Atul Sharma, MPH; Mike Hughes, MSc, PhD

Atul Sharma started working in Decision Resources Group as an intern in early 2016 and currently works as an associate epidemiologist. He performs fully documented systematic reviews of both published and grey literature on the epidemiology of assigned diseases and their risk factors to estimate incidence/prevalence over a 10-30 year period. He produces analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets. He holds a Master’s in Public Health degree from School of Public Health, Post-Graduate Institute of Medical Education and Research and a Bachelor’s in dental surgery from MN DAV Dental College & Hospital.

Mike joined Decision Resources as an epidemiologist in 2006. He has many years’ experience in the mathematical modeling of healthcare service delivery, cardiovascular and cancer epidemiology, biostatistics, meta-analysis and systematic reviewing. He has been principal author on many published articles in leading international journals in the areas of risk modeling in intensive care and cardiovascular medicine. He has also been responsible for developing national guidelines on behalf of NICE and the American College of Chest Physicians for the treatment of atrial fibrillation, stroke and hypertension. He is particularly interested in modeling patient flows in cancer and methods for forecasting disease burden in non-communicable epidemiology. Dr. Hughes received his in risk modeling in intensive care in 2003 from City University, London and is currently enrolled in a program in statistical causation and foundations of probability theory at the University of Nottingham.


Related Reports

Non-Small-Cell Lung Cancer | Unmet Need | Detailed, Expanded Analysis: EGFR-positive metastatic non-squamous NSCLC (US & EU)

EGFR-mutation-status determination is a mandatory step in the treatment algorithm for patients with advanced non-small-cell lung can...

View Details

Non-Small-Cell Lung Cancer | Landscape & Forecast | Disease Landscape & Forecast

Non-small-cell lung cancer (NSCLC) is one of the most dynamic oncology indications and a key area of focus for drug developers. Immune checkpoint i...

View Details

Non-Small-Cell Lung Cancer | Geographic Focus: China | Non-Small-Cell Lung Cancer | China In-Depth | China

MARKET OUTLOOK Non-small cell lung cancer (NSCLC) is one of the most commonly diagnosed cancers and the leading cause of cancer-related deaths in China. NSCLC has one of...

View Details

Non-Small-Cell Lung Cancer | Access & Reimbursement | Detailed, Expanded Analysis (EU)

MARKET OUTLOOK Non-small-cell lung cancer (NSCLC) has a high incidence and a large number of premium-priced therapies, wh...

View Details